FDA Approves Daraxonrasib, a Pancreatic Cancer Drug, Extending Life Expectancy

The Food and Drug Administration (FDA) has approved Daraxonrasib, an oral drug for pancreatic cancer that has shown to extend life expectancy for patients. This marks the first approved targeted therapy for pancreatic cancer patients, inhibiting RAS proteins at the molecular level, a type of cancer that impacts over 90% of diagnosed patients. Clinical trials indicated that patients taking Daraxonrasib averaged seven additional months of life compared to those receiving chemotherapy alone.